Request Trial
trademark-istock-508118711-timarbaev-
timarbaev / iStockphoto.com
11 January 2019Medtech

Plastic surgery clinic targets former employees in copyright and TM suit

A New York-based plastic surgery clinic has taken legal action against two former employees and a rival clinic for copyright infringement, trademark counterfeiting and dilution, and cybersquatting.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Could everyday hospital equipment be the next defence against counterfeit medicines?
23 February 2026   A new study suggests the equipment already found in hospitals worldwide could offer a front line against fake vaccines and insulin.
Medtech
Danaher moves to acquire Masimo in $9.9bn deal
18 February 2026   The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.
Medtech
Chinese invisible braces maker hits back at infringement claims
22 August 2025   The company has dismissed recent patent infringement claims from the Invisalign maker as “frivolous and entirely without merit,” pledging a vigorous defence.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

US biotech fires trade secrets suit at Chinese pharma group
Hikma v Amarin: Six takeaways from the pivotal ruling
Exclusive: ‘When a UPC judge wears their robe, they have no gender’
Clarivate’s new IP president to ‘usher in next phase of growth’
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
Ex-Kirkland patent litigator jumps to rival firm
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech